BCLI241115C1000
- 0.05
- 0.000.00%
Brainstorm Cell Therapeutics Newsroom
Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate
Brainstorm Cell Therapeutics | 10-Q: Quarterly report
Brainstorm Cell Therptcs 3Q Loss $2.71M >BCLI
Brainstorm Cell Therptcs 3Q Loss/Shr 51c >BCLI
Press Release: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Brainstorm Cell Therapeutics and Pluri Partner to Support Nurown® Phase 3B Trial Manufacturing
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing
Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating
Express News | Brainstorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
BrainStorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
BrainStorm CEO to Discuss Phase 3b ALS Trial at Maxim Healthcare Virtual Summit
Express News | Brainstorm Cell Therapeutics to Provide Corporate Update on Phase 3B Nurown® Trial at the 2024 Maxim Healthcare Virtual Summit
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Brainstorm Cell Therapeutics To Carry Out 1-for-15 Reverse Stock Split On October 1st, 2024
September 27th (Eastern Time) - $Brainstorm Cell Therapeutics(BCLI.US)$ is about to implement a 1-for-15 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from
12 Health Care Stocks Moving In Friday's After-Market Session
Express News | Brainstorm Cell Therapeutics - Approved One-for-Fifteen Reverse Stock Split of Co's Common Stock
Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating, Maintains Target Price $2
BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting
Brainstorm Cell Therapeutics Enacts Key Corporate Changes